CONFIDENTIAL

Product information

Allergic Rhinitis Protection Bentrio®

A drug-free, preservative-free nasal spray that forms a protective barrier on the nasal mucosa against airborne allergens



This presentation contains confidential information intended solely for the recipient and may not be shared without prior written consent by Altamira Medica AG

PRESENTED BY altamira medica

EXECUTIVE SUMMARY

Bentrio: Summary



Bentrio® Allergy · 20 mL · Drug-free

Regulatory

Class IIa over-the-counter medical device under EU MDR, approved by the Chinese authority.

Clinical evidence

Demonstrated efficacy in seasonal and year-round allergic rhinitis; published in the journal Allergy.

Category tailwind

Harnesses demand for natural, drug-free treatment.

Differentiated

Distinct from systemic antihistamines and decongestants.

Provenance

Developed in Switzerland, manufactured in Germany.

Patent protected

Patents granted in several key markets, including the United States.

Commercial proof at a premium price point

Real-life sales to patients at EUR 15–21 per unit in existing territories, for example Northern Europe and Hong Kong.

OUTLOOK — In-vitro data suggest a potential future indication to help prevent viral infection — pending further clinical studies.

PRODUCT OVERVIEW

Unique selling proposition, mode of action and contents

USP

The drug-free barrier spray with the world's best clinical evidence



Immediate effect, acts for up to 4 hours

Drug-free and preservative-free

Class IIa medical device under EU MDR, approved in China

Developed in Switzerland

MODE OF ACTION

Builds a purely physical gel barrier on the mucosa

Traps inhaled particles with electrostatic effects

Moisturizes the nasal mucosa

Liquefies upon application and re-forms as a gel on the nasal mucosa (the so-called thixotropic property)

CONTENTS

Bentonite

Natural mineral at the core

Gel emulsion

Medium-chain triglycerides and xanthan sustain the gel barrier

Purified water · medium-chain triglyceride (Miglyol® 812 N) · propylene glycol · bentonite · glycerol mono-/dipalmitostearate · xanthan · disodium EDTA · mannitol · citric acid · butylhydroxyanisole · vanillin

PRODUCT OVERVIEW

What Bentrio® is, why it is used, and how it works




WHAT — A drug- and preservative-free nasal spray based on natural bentonite that forms a physical gel barrier inside the nose.

WHY — Allergy sufferers need rapid relief without drowsiness, rebound congestion or drugs.

HOW — Sprayed as a fine mist, the thixotropic gel re-forms on the nasal lining to shield the mucosa, trap inhaled particles and moisturize — acts for up to 4 hours.

MECHANISM

A purely physical triple-action mechanism



SHIELDS

the nasal mucosa with a physical gel barrier.

TRAPS

inhaled particles such as pollen and allergens.

MOISTURIZES

the nasal mucosa, supporting its natural function.

▸ Mode-of-action video

POSITIONING

Bridging the gap between saline and medicated sprays

MEDICATED NASAL SPRAYS







Effective — but carry a drug burden and side effects

THE WHITE SPACE



Bentrio®

Non-medicated, but more than saline: a triple-action barrier that protects and alleviates

SALINE & SEA WATER







Drug-free and gentle — but limited efficacy

Note: third-party product names, logos and packaging shown are trademarks and/or trade dress of their respective owners, referenced solely for market-positioning purposes. No affiliation, sponsorship or endorsement by these companies is implied.

KEY MESSAGES

Fast, powerful, and free of harmful substances



Fast

Starts working immediately upon application.



Powerful

Triple action shields the mucosa, traps particles and moisturizes.



Free

No drugs, no preservatives — with natural bentonite.

- Acts for up to 4 hours
- Prescription-free
- Suitable during pregnancy & breastfeeding
- Developed in Switzerland
- Clinically proven efficacy

CLINICAL EVIDENCE

Strong randomised data in allergic rhinitis

STUDY	DESIGN & POPULATION	N	COMPARATOR	KEY OUTCOME
Becker 2024 Allergy — “NASAR”	Two-week randomised, parallel, outpatient seasonal allergic rhinitis (Australia)	**100**	Saline spray	Mean daily symptom score −1.1 (p = 0.013); quality of life 3× better; relief-medication use 2.6× lower
Couroux 2023 Clin Transl Allergy	Triple-crossover challenge, year-round allergy (house dust mite)	**37**	No treatment	Significant symptom reduction throughout 3 h; fast onset
Salapatek 2023 JACI	Crossover challenge, seasonal allergic rhinitis	**36**	No treatment; cellulose powder	Symptom score −1.09 versus none (p < 0.0001); effect 3–4 h; preferred over the powder
Sailer 2023 Drug Dev Ind Pharm	Fluorescent-tracer imaging, healthy volunteers	**8**	—	Uniform mucosal coating about 4 h after a single spray; well tolerated

Contact

Philip Winzeler

CEO

philip.winzeler@altamiramedica.com

Heiko Walzinger

COO and Business Development

heiko.walzinger@altamiramedica.com

ONLINE

www.bentrio.com

www.altamiramedica.com

Confidential